全文获取类型
收费全文 | 37723篇 |
免费 | 4492篇 |
国内免费 | 1491篇 |
专业分类
耳鼻咽喉 | 224篇 |
儿科学 | 683篇 |
妇产科学 | 420篇 |
基础医学 | 3532篇 |
口腔科学 | 766篇 |
临床医学 | 3526篇 |
内科学 | 5030篇 |
皮肤病学 | 279篇 |
神经病学 | 2260篇 |
特种医学 | 2464篇 |
外国民族医学 | 9篇 |
外科学 | 5230篇 |
综合类 | 6173篇 |
现状与发展 | 4篇 |
预防医学 | 3381篇 |
眼科学 | 1590篇 |
药学 | 4525篇 |
19篇 | |
中国医学 | 1821篇 |
肿瘤学 | 1770篇 |
出版年
2024年 | 81篇 |
2023年 | 465篇 |
2022年 | 1195篇 |
2021年 | 1560篇 |
2020年 | 1429篇 |
2019年 | 1396篇 |
2018年 | 1384篇 |
2017年 | 1394篇 |
2016年 | 1461篇 |
2015年 | 1447篇 |
2014年 | 2400篇 |
2013年 | 2634篇 |
2012年 | 2425篇 |
2011年 | 2563篇 |
2010年 | 2053篇 |
2009年 | 1847篇 |
2008年 | 2035篇 |
2007年 | 2024篇 |
2006年 | 1906篇 |
2005年 | 1688篇 |
2004年 | 1432篇 |
2003年 | 1243篇 |
2002年 | 1024篇 |
2001年 | 925篇 |
2000年 | 800篇 |
1999年 | 645篇 |
1998年 | 470篇 |
1997年 | 481篇 |
1996年 | 398篇 |
1995年 | 401篇 |
1994年 | 317篇 |
1993年 | 269篇 |
1992年 | 248篇 |
1991年 | 190篇 |
1990年 | 166篇 |
1989年 | 121篇 |
1988年 | 117篇 |
1987年 | 122篇 |
1986年 | 85篇 |
1985年 | 176篇 |
1984年 | 144篇 |
1983年 | 126篇 |
1982年 | 102篇 |
1981年 | 87篇 |
1980年 | 79篇 |
1979年 | 45篇 |
1978年 | 32篇 |
1977年 | 24篇 |
1976年 | 18篇 |
1973年 | 13篇 |
排序方式: 共有10000条查询结果,搜索用时 234 毫秒
51.
C. M. Gordon E. Binello M. S. LeBoff M. E. Wohl C. J. Rosen A. A. Colin 《Osteoporosis international》2006,17(5):783-790
Introduction Patients with cystic fibrosis (CF) are known to be at risk for early osteoporosis, and the mechanisms that mediate bone loss
are still being delineated. The aim of the present investigation was to investigate if a correlation exists in these patients
between skeletal measurements by dual-energy x-ray absorptiometry (DXA) and two anabolic factors, dehydroepiandrosterone (DHEA)
and insulin-like growth factor I (IGF-I), and proresorptive factors such as the cytokines interleukin-1β, tumor necrosis factor α,
and interleukin-6.
Methods We studied 32 outpatients (18 females; mean age: 26.2 ± 7.9 years) at a tertiary care medical center. The subjects had venous
samples obtained, underwent anthropometric and bone mineral density (BMD) measurements, and completed a health survey. Serum
IGF-I concentrations were below the age-adjusted mean in 78% of the participants, and DHEA sulfate (DHEAS) concentrations
were low in 72%. Serum concentrations of all cytokines were on the low side of normal; nonetheless, there was a modest inverse
correlation between IL-1β and BMD at all sites.
Results In univariate analyses, IGF-I and DHEAS were significant correlates of BMD or bone mineral content. In final multivariate
models controlling for anthropometric and other variables of relevance to bone density, only IGF-I was identified as a significant
independent skeletal predictor. While alterations in DHEAS, IGF-I, and specific cytokines may contribute to skeletal deficits
in patients with CF, of these factors a low IGF-I concentration appears to be most strongly correlated with BMD.
Conclusions These findings may have therapeutic implications for enhancing bone density in these patients. 相似文献
52.
老年女性2型糖尿病肾病的骨密度及相关因素分析 总被引:1,自引:0,他引:1
2型糖尿病(T2DM)和骨质疏松症的发病率越来越高,它们之间有无关系越来越引起人们的重视,本研究探讨了老年女性2型糖尿病肾病(DN)的骨矿物质密度(BMD)变化与相关因素,报道如下。1对象与方法1.1研究对象按1999年WHO诊断标准确诊为T2DM的≥60岁女性114例,年龄60~75岁,平均(66.3± 相似文献
53.
Haruhito Adam Uchida Yoshio Nakamura Masanobu Kaihara Hisanao Norii Yoshihisa Hanayama Hitoshi Sugiyama Yohei Maeshima Yasushi Yamasaki Hirofumi Makino 《Nephrology, dialysis, transplantation》2006,21(12):3475-3480
BACKGROUND: Decreased plasma adiponectin is associated with impaired endothelial function and, thereby, increased risk for cardiovascular events. Glucocorticoid (GC) affects vascular endothelial cells either favourably or harmfully depending upon the dosages and duration. We examined the effect of GC pulse therapy on vascular endothelial function. METHODS: Fourteen young patients with IgA nephropathy were evaluated for flow-mediated vasodilation (FMD), plasma levels of adiponectin both in high molecular weight (HMW adiponectin) form and in single molecular form (total adiponectin), hepatocyte growth factor (HGF), asymmetric dimethylarginine (ADMA), and high-sensitive C-reactive protein, before and after a course of GC pulse therapy. RESULTS: GC pulse therapy significantly decreased FMD (from 7.2 +/- 2.6 to 5.7 +/- 2.5%, P < 0.01). Meanwhile, plasma adiponectin levels were significantly augmented (total adiponectin: from 10.2 +/- 4.0 to 12.1 +/- 6.3 microg/ml, P < 0.05; HMW: from 6.5 +/- 3.2 to 7.7 +/- 3.3 microg/ml, P < 0.05). In parallel, elevated concentrations of serum HGF (from 0.28 +/- 0.12 to 0.63 +/- 0.38 ng/ml, P < 0.01) and plasma ADMA (from 0.45 +/- 0.07 to 0.53 +/- 0.04 nmol/ml, P < 0.05) were observed. CONCLUSIONS: GC pulse therapy impaired endothelial function while increasing plasma adiponectin levels, which may in turn restore the endothelial function in patients with IgA nephropathy. 相似文献
54.
R. P. Heaney T. M. Zizic I. Fogelman W. P. Olszynski P. Geusens C. Kasibhatla N. Alsayed G. Isaia M. W. Davie C. H. Chesnut III 《Osteoporosis international》2002,13(6):501-505
Risedronate treatment reduces the risk of vertebral fracture in women with existing vertebral fractures, but its efficacy
in prevention of the first vertebral fracture in women with osteoporosis but without vertebral fractures has not been determined.
We examined the risk of first vertebral fracture in postmenopausal women who were enrolled in four placebo-controlled clinical
trials of risedronate and who had low lumbar spine bone mineral density (BMD) (mean T-score =–3.3) and no vertebral fractures at baseline. Subjects received risedronate 5 mg (n= 328) or placebo (n= 312) daily for up to 3 years; all subjects were given calcium (1000 mg daily), as well as vitamin D supplementation (up
to 500 IU daily) if baseline serum 25-hydroxyvitamin D levels were low. The incidence of first vertebral fracture was 9.4%
in the women treated with placebo and 2.6% in those treated with risedronate 5 mg (risk reduction of 75%, 95% confidence interval
37% to 90%; P= 0.002). The number of patients who would need to be treated to prevent one new vertebral fracture is 15. When subjects were
stratified by age, similar significant reductions were observed in patients with a mean age of 64 years (risk reduction of
70%, 95% CI 8% to 90%; P= 0.030) and in those with a mean age of 76 years (risk reduction of 80%, 95% CI 7% to 96%; P= 0.024). Risedronate treatment therefore significantly reduces the risk of first vertebral fracture in postmenopausal women
with osteoporosis, with a similar magnitude of effect early and late after the menopause.
Received: 12 September 2001 / Accepted: 11 December 2001 相似文献
55.
目的:研究水杨醛-N′-(2-呋喃硫羰基)腙铜配合物(CSFC)在兔体内的药物动力学。方法:10只家兔静脉注射CSFC5mg·kg-1,用反相HPLC法测定血清药物浓度。结果:CSFC的血药浓度-时间曲线符合二室开放模型,主要药动学参数为:T12α=3.4±1.7min,T12β=65.5±14.6min,K12=0.1183±0.0669min-1,K21=0.0228±0.0065min-1,K10=0.1202±0.0407min-1,V0=0.305±0.184L·kg-1,CL=1.896±0.470L·kg-1·h-1,AUC=170.1±57.0mg·min-1·L-1。结论:CSFC在兔体内分布迅速而广泛,消除也较快。家兔静注5mg·kg-1,可维持抗结核杆菌有效血浓度6h。 相似文献
56.
Prevention of Bone Loss by Clodronate in Early Postmenopausal Women with Vertebral Osteopenia: A Dose-Finding Study 总被引:1,自引:0,他引:1
M. J. V?lim?ki K. Laitinen K. Laitinen A. Patronen H. Puolijoki H. Puolijoki J. Sepp?nen L. Pylkk?nenand the Probone Study Group 《Osteoporosis international》2002,13(12):937-947
This double-masked, placebo-controlled study was undertaken to determine the efficacy and safety of oral clodronate in the
prevention of bone loss in early postmenopausal women with vertebral osteopenia. Altogether 610 women with a mean age of 53
years were recruited for the study. They were 1–5 years postmenopausal and their lumbar spine bone mineral density (BMD) was
at least 1 standard deviation below the mean of premenopausal women (T-score ≤−1). The subjects were randomized into five study groups to receive either placebo, clodronate 65 mg, 400 mg or 800
mg daily, or intermittent clodronate in 3 month cycles with 400 mg daily for 15 days followed with no treatment for 75 days
for 3 years. One hundred and eighty-seven of 509 women who completed the primary study continued in the extension study of
2 years in which previous placebo users were switched to clodronate 800 mg daily, while previous users of 400 mg or 800 mg
of clodronate used either placebo or 800 mg of clodronate daily. In the primary study clodronate was administered in the evening,
and in the extension 1 h before breakfast on an empty stomach. In the primary study mean changes in lumbar spine BMD were
−3.4% in the placebo group and +0.4% in 800 mg clodronate group [difference between groups at 3 years 3.8% (95% CI 2.7% to
4.9%, p<0.0001)], and in the trochanter area BMD −1.1% in the placebo group, and + 0.4% in the 800 mg clodronate group [difference
between groups at 3 years 1.5% (95% CI 0.05% to 2.9%)]. During the extension study mean changes in lumbar spine BMD were +1.5%
in the clodronate group and −0.2 % in the placebo group [difference between groups 1.7% (CI 0.4% to 3.0%, p = 0.010)] and in trochanter BMD were +2.5% in the clodronate group and no change in the placebo group [difference between
groups 2.1% (CI 0.3% to 3.9%, p = 0.007)]. No statistically significant differences between the placebo and 800 mg clodronate groups were found in the femoral
neck BMD. In the primary study the urinary excretion of type I collagen aminoterminal telopeptide (NTX) decreased by 44% (p<0.0001 compared with placebo) and that of deoxypyridinoline by 18% (p<0.0001) in the clodronate 800 mg group. In the extension study urinary NTX decreased by 51% (p<0.0001) in those who were switched to 800 mg of clodronate and increased by 67% (p<0.0001) in those who stopped using that dose. There was no difference in the frequency of gastrointestinal complaints between
clodronate- and placebo-treated patients in the primary study, but they were more common among women who received clodronate
in the extension phase. Clodronate in daily doses of 400–800 mg caused a slight elevation of aminotransferase levels, usually
within the reference range. In bone biopsies no defect in mineralization was found. In conclusion, clodronate in a daily dose
of 800 mg prevents early postmenopausal bone loss at the sites of the skeleton in which cancellous bone predominates. It effectively
reduces bone resorption and bone turnover rate. Antifracture efficacy of clodronate remains to be established by prospective,
placebo-controlled trials.
Received: 4 March 2002 / Accepted: 9 July 2002 相似文献
57.
目的 :研究老年人不同疾病时骨密度 (BMD)的分布情况。方法 :用DXADAS 6 0 0EX型骨密度仪对183例老年患者进行左侧远程桡骨加尺骨BMD检测。结果 :内分泌疾病组、消化道疾病组和其它疾病组的患病率分别为 72 7% ,2 0 6 %和 31 4 %。T值比较 :三组差异明显 (P <0 0 0 1)。累积骨丢失率 (ABLR)比较 :前一组明显高于后两组病人 (P <0 0 1)。BMD比较中 ,内分泌和其它疾病组明显低于消化道疾病组 (P <0 0 0 1)。相关分析显示 ,内分泌和消化道疾病组的年龄变化与BMD呈正相关 (r =0 5 19P <0 0 0 1和r =0 5 89P <0 0 0 1) ,内分泌疾病组和其它疾病组的体重变化与BMD呈正相关 (r=0 918P <0 0 0 1和r =0 338P <0 0 0 1)。结论 :老年人骨质疏松 (OP)患病率以内分泌疾病组最高 ,消化道疾病组较低 ;随年龄和体重增加 ,BMD降低加重。 相似文献
58.
59.
Zongli Lin Meir Pachter Siva Banda Yacov Shamash 《Optimal control applications & methods.》2002,23(1):21-43
A design technique (Control of Uncertain Systems with Bounded Inputs, Tarbouriech S, Garcia G, (Eds), Lecture Notes in Control and Information Sciences, vol. 227 , Springer: Berlin, 1997; 173–186) recently proposed for stabilization of a linear system with rate‐limited actuators is utilized to design feedback laws that cause the system output to track a desired command signal. This design technique combines two design techniques recently developed for linear systems with position limited actuators, piecewise‐linear LQ control (Automatica, 1994; 30 : 403–416) and low‐and‐high gain feedback (IEEE Trans. Automat. Control, 1996; 41 : 368–378), and hence takes advantage of both design techniques, while avoiding their disadvantages. In the case that only the output is available for feedback, the performance of the state feedback law is preserved by the use of a fast observer. An open‐loop exponentially unstable fighter aircraft is used to demonstrate the effectiveness of the proposed control design method. Copyright © 2002 John Wiley & Sons, Ltd. 相似文献
60.
河南食管癌高、低发区无症状人群食管固有膜血管乳头的变化 总被引:2,自引:1,他引:1
目的:探讨食管癌高、低发区无症状居民食管上皮固有膜血管乳头(简称乳头)增生特征(乳头密度和高度)及其与病变分布的关系,加深对食管癌变早期形态学变化特征的了解。方法:2480例无症状人群食管粘膜活检组织,采用食管癌高低发区食管纤维内镜检查,粘膜活检,组织病理学检查和形态学测量技术对食管乳头的分布特征及其与病变的关系进行分析。结果:食管癌高低发区居民食管中、下段乳头升高(≥上皮厚度的1/2)发生率之间差异并不明显(P>0.05),但是,高发区居民食管中段乳头密度(乳头数目/mm)明显高于下段,并高于低发区居民食管中段的乳头密度(P<0.05);高发区居民食管上皮乳头升高伴基底细胞过度增生患者明显高于正常人(P<0.05),而低发区未观察到类似情况。结论:乳头增生表现为乳头数目增多和乳头升高是食管癌高发区人群食管上皮特征性形态学变化,高分区居民上皮乳头升高伴明显基底细胞过度增生,提示乳头增生可能是食管癌变极早期阶段的重要形态学变化,反映了上皮细胞的增生状态。 相似文献